<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003623'>Neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>) is a rare, <z:hpo ids='HP_0011463'>childhood-onset</z:hpo> disease that is characterized by <z:hpo ids='HP_0011010'>chronic</z:hpo>, systemic <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this report is to describe the effects of interleukin-1 (IL-1) blockade on the clinical symptoms of 2 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>At the time of this report, the patients had been treated with anakinra (Kineret), a recombinant human IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, for 1.5 and 2 years, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Both patients demonstrated rapid improvement in clinical symptoms and laboratory markers of <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>The use of anakinra in these patients seemed to be effective, without any safety concerns </plain></SENT>
<SENT sid="5" pm="."><plain>These observations suggest that IL-1 plays a critical role in the pathogenesis of this <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, and that blockade with anakinra should be further studied as a treatment for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e> and related disorders </plain></SENT>
</text></document>